This possibility is exemplified by the fact that CXCR1/2 inhibition by the antagonist SCH563705 has given rise to inhibition of spheroid formation in HER2+ breast tumor cells, and inhibition of HER2-mediated signaling by lapatinib or siHER2 has led to inhibition of CXCR1/2-dependent CSC-spheroid formation (79). The gene discussed is ERBB2; the disease is breast neoplasm.